The U.S. Food and Drug Administration (FDA) has rolled out fresh draft guidance on “Regulatory Considerations for Prescription Drug Use-Related Software” (PDS Guidance). The new instructions, as outlined by the FDA, articulate how they plan to apply their drug labeling authorities towards certain software outputs. Such outputs are communicated by or on behalf of a drug sponsor, and are intended to be used with a prescription drug or a prescription drug-led. The last term implies that it can either be under the purview of the Center for Drug Evaluation and Research (CDER) or the Center for Biologics Evaluation and Research (CBER).
For more details on the new FDA draft guidance, click here.